Prevalence of Regular Gynecological Follow-up Among Women of Childbearing Age (Suivi-gynéco)

February 13, 2026 updated by: Université de Reims Champagne-Ardenne

The French National Authority for Health (Haute Autorité de Santé, HAS) recommends regular gynecological follow-up, specifying that it is considered regular when it is annual. The objectives of this gynecological follow-up are multiple: to support women in the choice and management of contraception as well as in their sexuality; to screen for cervical cancer and breast cancer; to diagnose and to take care of sexually transmitted infections (STIs); and to diagnose and treat gynecological conditions such as adenomyosis, endometriosis, polycystic ovary syndrome, etc. Regarding cervical cancer screening, the HAS recommends performing a Pap smear (cervical cytology) starting at the age of 25 and up to the age of 65.

Several studies, such as those by Henry et al. in 2020 and Owokuhaisa et al. in 2024, have identified major barriers to access to gynecological care for women. These barriers include very long waiting times, lack of privacy, lack of understanding or access to appropriate information, discomfort or fear during consultations, shortage of physicians, past negative experiences, etc. These factors may contribute to women postponing or even forgoing their gynecological consultations. A study by Landy et al. in 2021 also showed that women diagnosed with advanced-stage cervical cancer had not undergone regular screening or gynecological follow-up.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Objectives Primary: To describe the prevalence of regular gynecological follow-up among women of childbearing age.

Secondary:

  • To describe women's knowledge regarding gynecological follow-up
  • To investigate the factors associated with women's regular gynecological follow-up, particularly the desire for pregnancy

Study Type

Observational

Enrollment (Actual)

395

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Reims, France, 51100
        • Ufr Medecine Urca

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Adult women, non-menopausal, with or without desire for pregnancy, not pregnant, and agreeing to participate in the study

Description

Inclusion Criteria:

  • Women aged 18 years and over
  • Are not menopausal
  • Have or do not have a desire for pregnancy
  • Have children or do not have children
  • Have a sexual partner or not
  • Reside in metropolitan France or in the French overseas department.
  • Agreeing to participate in the study

Exclusion Criteria:

  • Being pregnant
  • Being legally protected (guardianship, curatorship, judicial protection)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prevalence of regular gynecological follow-up
Time Frame: Day 0
Regular gynecological follow-up (according to HAS recommendations: once per year) and, if irregular, the frequency of follow-up: once every two to three years, occasionally, more than three years ago, or never consulted
Day 0

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Université de Reims Champagne-Ardenne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2025

Primary Completion (Actual)

January 30, 2026

Study Completion (Actual)

February 1, 2026

Study Registration Dates

First Submitted

February 13, 2026

First Submitted That Met QC Criteria

February 13, 2026

First Posted (Actual)

February 20, 2026

Study Record Updates

Last Update Posted (Actual)

February 20, 2026

Last Update Submitted That Met QC Criteria

February 13, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025_RIPH_17_SF_A Fillion

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gynecological Follow-up

Clinical Trials on data collection

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe